Respiratory Syncytial Virus Vaccination Recommendations for Adults Aged 60 Years and Older: The NeumoExperts Prevention Group Position Paper / Recomendaciones de vacunación contra el virus sincitial respiratorio para adultos de 60 años o más: documento de posición del grupo de prevención NeumoExperts

Respiratory syncytial virus (RSV) is a major cause of respiratory tract infections in adults, particularly older adults and those with underlying medical conditions. Vaccination has emerged as a potential key strategy to prevent RSV-related morbidity and mortality. This Neumoexperts Prevention (NEP) Group scientific paper aims to provide an evidence-based positioning and RSV vaccination recommendations for adult patients. We review the current literature on RSV burden and vaccine development and availability, emphasising the importance of vaccination in the adult population. According to our interpretation of the data, RSV vaccines should be part of the adult immunisation programme, and an age-based strategy should be preferred over targeting high-risk groups. The effectiveness and efficiency of this practice will depend on the duration of protection and the need for annual or more spaced doses. Our recommendations should help healthcare professionals formulate guidelines and implement effective vaccination programmes for adult patients at risk of RSV infection now that specific vaccines are available.(AU)

Respiratory Syncytial Virus Vaccination Recommendations for Adults Aged 60 Years and Older: The NeumoExperts Prevention Group Position Paper.

Respiratory syncytial virus (RSV) is a major cause of respiratory tract infections in adults, particularly older adults and those with underlying medical conditions. Vaccination has emerged as a potential key strategy to prevent RSV-related morbidity and mortality. This Neumoexperts Prevention (NEP) Group scientific paper aims to provide an evidence-based positioning and RSV vaccination recommendations for adult patients. We review the current literature on RSV burden and vaccine development and availability, emphasising the importance of vaccination in the adult population. According to our interpretation of the data, RSV vaccines should be part of the adult immunisation programme, and an age-based strategy should be preferred over targeting high-risk groups. The effectiveness and efficiency of this practice will depend on the duration of protection and the need for annual or more spaced doses. Our recommendations should help healthcare professionals formulate guidelines and implement effective vaccination programmes for adult patients at risk of RSV infection now that specific vaccines are available.

Cost-utility analysis of the use of the 20-valent anti-pneumococcal vaccine (PCV20) in adults older than 60 years in Spain.

BACKGROUND AND OBJECTIVES: A cost-utility analysis was conducted to assess the efficiency of implementing a PCV20 vaccination strategy in the Spanish adult population older than 60 years, for the prevention of non-bacteremic pneumococcalpneumonia (NBP) and invasive pneumococcal disease (IPD). METHODS: A Markov model, with annual cycles and a time horizon of 10 years was used. The analysis population was stratified by age and risk groups. The comparator was the sequential vaccination with the 15-valent pneumococcal conjugate vaccine (PCV15) followed by one dose of the pneumococcal polysaccharide vaccine (PPV23). The base case analysis was performed from the National Healthcare System (NHS) perspective including direct costs (€2018) and applying a discount of 3% to future costs and outcomes. Alternative scenarios explored a shorter time horizon (5 years), the societal perspective and other available vaccination strategies. All the parameters and assumptions were validated by a panel of experts. To evaluate the robustness of the model, deterministic and probabilistic sensitivity analyses (PSA) were carried out. RESULTS: The results of the study showed that the vaccination strategy with PCV20 is a dominant option compared to the sequential regimen (PCV15 + PPSV23), resulting in direct cost savings of €85.7 M over 10 years, with a small increase in quality-adjusted life years (QALYs). PCV20 vaccination avoided 2,161 cases of IPD, 19,470 of NBP and 3,396 deaths and according to the PSA, the probability of PCV20 being cost-effective compared to a sequential regimen (PCV15 + PPSV23) was 100%. CONCLUSIONS/RECOMMENDATIONS: In the Spanish adult population older than 60 years, the vaccination strategy with one dose of PCV20 is more effective and less expensive (dominant) than vaccination with a sequential schedule with PCV15 and PPSV23.

Executive summary - Diagnosis, treatment and prophylaxis of influenza virus infection - Consensus statement of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish Society of Pediatric Infectious Diseases (SEIP), the Spanish Association of Vaccinology (AEV), the Spanish Society of Family and Community Medicine (SEMFYC) and the Spanish Society of Preventive Medicine, Public Health and Health Management (SEMPSPGS).

The influenza virus has accompanied humans since time immemorial, in the form of annual epidemics and occasional pandemics. It is a respiratory infection with multiple repercussions on people's lives at an individual and social level, as well as representing a significant burden on the health system. This Consensus Document arises from the collaboration of various Spanish scientific societies involved in influenza virus infection. The conclusions drawn are based on the highest quality evidence available in the scientific literature and, failing that, on the opinion of the experts convened. The Consensus Document addresses the clinical, microbiological, therapeutic, and preventive aspects (with respect to the prevention of transmission and in relation to vaccination) of influenza, for both adult and pediatric populations. This Consensus Document aims to help facilitate the clinical, microbiological, and preventive approach to influenza virus infection and, consequently, to reduce its important consequences on the morbidity and mortality of the population.

Executive summary. Diagnosis, treatment and prophylaxis of influenza virus infection. Consensus statement of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish Society of Pediatric Infectious Diseases (SEIP), the Spanish Association of Vaccinology (AEV), the Spanish Society of Family and Community Medicine (SEMFYC) and the Spanish Society of Preventive Medicine, Public Health and Health Management (SEMPSPGS).

The influenza virus has accompanied humans since time immemorial, in the form of annual epidemics and occasional pandemics. It is a respiratory infection with multiple repercussions on people's lives at an individual and social level, as well as representing a significant burden on the health system. This Consensus Document arises from the collaboration of various Spanish scientific societies involved in influenza virus infection. The conclusions drawn are based on the highest quality evidence available in the scientific literature and, failing that, on the opinion of the experts convened. The Consensus Document addresses the clinical, microbiological, therapeutic, and preventive aspects (with respect to the prevention of transmission and in relation to vaccination) of influenza, for both adult and pediatric populations. This Consensus Document aims to help facilitate the clinical, microbiological, and preventive approach to influenza virus infection and, consequently, to reduce its important consequences on the morbidity and mortality of the population.

Executive summary. Diagnosis, treatment and prophylaxis of influenza virus infection. Consensus statement of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish Society of Pediatric Infectious Diseases (SEIP), the Spanish Association of Vaccinology (AEV), the Spanish Society of Family and Community Medicine (SEMFYC) and the Spanish Society of Preventive Medicine, Public Health and Health Management (SEMPSPGS).

The influenza virus has accompanied humans since time immemorial, in the form of annual epidemics and occasional pandemics. It is a respiratory infection with multiple repercussions on people's lives at an individual and social level, as well as representing a significant burden on the health system. This Consensus Document arises from the collaboration of various Spanish scientific societies involved in influenza virus infection. The conclusions drawn are based on the highest quality evidence available in the scientific literature and, failing that, on the opinion of the experts convened. The Consensus Document addresses the clinical, microbiological, therapeutic, and preventive aspects (with respect to the prevention of transmission and in relation to vaccination) of influenza, for both adult and pediatric populations. This Consensus Document aims to help facilitate the clinical, microbiological, and preventive approach to influenza virus infection and, consequently, to reduce its important consequences on the morbidity and mortality of the population.

Vaccination against Community-Acquired Pneumonia in Spanish Adults: Practical Recommendations by the NeumoExperts Prevention Group.

In the adult population, community-acquired pneumonia (CAP) is a serious disease that is responsible for high morbidity and mortality rates, being frequently associated with multidrug resistant pathogens. The aim of this review is to update a practical immunization prevention guideline for CAP in Spain caused by prevalent respiratory pathogens, based on the available scientific evidence through extensive bibliographic review and expert opinion. The emergence of COVID-19 as an additional etiological cause of CAP, together with the rapid changes in the availability of vaccines and recommendations against SARS-CoV-2, justifies the need for an update. In addition, new conjugate vaccines of broader spectrum against pneumococcus, existing vaccines targeting influenza and pertussis or upcoming vaccines against respiratory syncytial virus (RSV) will be very useful prophylactic tools to diminish the burden of CAP and all of its derived complications. In this manuscript, we provide practical recommendations for adult vaccination against the pathogens mentioned above, including their contribution against antibiotic resistance. This guide is intended for the individual perspective of protection and not for vaccination policies, as we do not pretend to interfere with the official recommendations of any country. The use of vaccines is a realistic approach to fight these infections and ameliorate the impact of antimicrobial resistance. All of the recently available scientific evidence included in this review gives support to the indications established in this practical guide to reinforce the dissemination and implementation of these recommendations in routine clinical practice.

Development and evaluation of a machine learning-based in-hospital COVID-19 disease outcome predictor (CODOP): A multicontinental retrospective study.

New SARS-CoV-2 variants, breakthrough infections, waning immunity, and sub-optimal vaccination rates account for surges of hospitalizations and deaths. There is an urgent need for clinically valuable and generalizable triage tools assisting the allocation of hospital resources, particularly in resource-limited countries. We developed and validate CODOP, a machine learning-based tool for predicting the clinical outcome of hospitalized COVID-19 patients. CODOP was trained, tested and validated with six cohorts encompassing 29223 COVID-19 patients from more than 150 hospitals in Spain, the USA and Latin America during 2020-22. CODOP uses 12 clinical parameters commonly measured at hospital admission for reaching high discriminative ability up to 9 days before clinical resolution (AUROC: 0·90-0·96), it is well calibrated, and it enables an effective dynamic risk stratification during hospitalization. Furthermore, CODOP maintains its predictive ability independently of the virus variant and the vaccination status. To reckon with the fluctuating pressure levels in hospitals during the pandemic, we offer two online CODOP calculators, suited for undertriage or overtriage scenarios, validated with a cohort of patients from 42 hospitals in three Latin American countries (78-100% sensitivity and 89-97% specificity). The performance of CODOP in heterogeneous and geographically disperse patient cohorts and the easiness of use strongly suggest its clinical utility, particularly in resource-limited countries.

While COVID-19 vaccines have saved millions of lives, new variants, waxing immunity, unequal rollout and relaxation of mitigation strategies mean that the pandemic will keep on sending shockwaves across healthcare systems. In this context, it is crucial to equip clinicians with tools to triage COVID-19 patients and forecast who will experience the worst forms of the disease. Prediction models based on artificial intelligence could help in this effort, but the task is not straightforward. Indeed, the pandemic is defined by ever-changing factors which artificial intelligence needs to cope with. To be useful in the clinic, a prediction model should make accurate prediction regardless of hospital location, viral variants or vaccination and immunity statuses. It should also be able to adapt its output to the level of resources available in a hospital at any given time. Finally, these tools need to seamlessly integrate into clinical workflows to not burden clinicians. In response, Klén et al. built CODOP, a freely available prediction algorithm that calculates the death risk of patients hospitalized with COVID-19 (https://gomezvarelalab.em.mpg.de/codop/). This model was designed based on biochemical data from routine blood analyses of COVID-19 patients. Crucially, the dataset included 30,000 individuals from 150 hospitals in Spain, the United States, Honduras, Bolivia and Argentina, sampled between March 2020 and February 2022 and carrying most of the main COVID-19 variants (from the original Wuhan version to Omicron). CODOP can predict the death or survival of hospitalized patients with high accuracy up to nine days before the clinical outcome occurs. These forecasting abilities are preserved independently of vaccination status or viral variant. The next step is to tailor the model to the current pandemic situation, which features increasing numbers of infected people as well as accumulating immune protection in the overall population. Further development will refine CODOP so that the algorithm can detect who will need hospitalisation in the next 24 hours, and who will need admission in intensive care in the next two days. Equipping primary care settings and hospitals with these tools will help to restore previous standards of health care during the upcoming waves of infections, particularly in countries with limited resources.

Norovirus: ¿un huésped más en residencias de la tercera edad? / Norovirus: One more guest in residential homes for the elderly?

No disponible

[Invasive neumococcal disease in Costa del Sol Hospital: replacement by non-vaccinable serotypes]. / Enfermedad neumocócica invasiva en el Hospital Costa del Sol: emergencia de serotipos no vacunables.

OBJECTIVE: Streptococcus pneumoniae can cause invasive and noninvasive diseases. Invasive pneumococcal disease causes infections in tissues, organs and fluids that are normally sterile and is associated with severe clinical processes generally. The aim of this study was to characterize ENI episodes as well as to describe the antimicrobial susceptibility and distribution of serotypes (vaccinal and non-vacunal) of S. pneumoniae strains isolated in blood cultures of patients treated at the Hospital Costa del Sol between September 2012 and January 2017. METHODS: Descriptive study from S. pneumoniae strains isolated in blood cultures. The variables studied were: age, sex, death, smoking, HIV infection, clinical diagnosis, serotype and antibiotic susceptibility profile. The source of information used was the clinic management program called Doctor. RESULTS: 76 S. pneumoniae strains were isolated. The most prevalent serotypes were 8, 3, 9N, 6C, 22F, 11A and 14. 77.3% of the strains were responsible for IPD (Invasive Pneumococcal Disease) episodes with clinical diagnosis of bacterial pneumonia. According to the CLSI 2016 (Clinical & Laboratory Standards Institute) criteria, 2 strains were non-susceptible to penicillin, 23 strains were non-susceptible to erythromycin and 3 were strains non-susceptible to levofloxacin. CONCLUSIONS: The results of this study show that the most frequent serotypes among ENI patients attended in our hospital are not covered by conjugate vaccines, although they do so by VNP23. Serotype 6C, not covered by any vaccine, was among the three most frequently isolated, causing death in one third of patients.

OBJETIVO: Streptococcus pneumoniae puede causar enfermedades invasivas y no invasivas. Bajo la denominación de enfermedad neumocócica invasiva, se incluyen aquellas infecciones que se localizan en tejidos, órganos y fluidos que normalmente son estériles y que se asocian con procesos clínicos generalmente severos. El objetivo de este estudio fue caracterizar los episodios de ENI (Enfermedad Neumocócica Invasiva) así como describir la sensibilidad antimicrobiana y distribución de los serotipos (vacunales y no vacunales) de cepas de S. pneumoniae aisladas en hemocultivos de pacientes atendidos en el Hospital Costa del Sol entre septiembre de 2012 y enero de 2017. METODOS: Estudio descriptivo a partir de cepas de S. pneumoniae aisladas en hemocultivos. Las variables de estudio fueron: edad, sexo, fallecimiento, tabaquismo, infección por VIH, diagnóstico clínico, serotipo y perfil de sensibilidad antimicrobiana. La fuente de información utilizada fue el programa de gestión clínica "Doctor". El análisis estadístico se llevó a cabo mediante el software SPSS (SPSS, version 15,0; SPSS, Chicago Illinois, USA). RESULTADOS: Se aislaron un total de 76 cepas de S. pneumoniae. Los serotipos más prevalentes fueron, en orden descendente 8, 3, 9N, 6C, 22F, 11A y 14. El 77,3% de las cepas fueron causantes de episodios de ENI con diagnóstico clínico de neumonía bacteriémica. Según el criterio del CLSI 2016 (Clinical & Laboratory Standards Institute), encontramos 2 cepas no sensibles a penicilina, 23 cepas no sensibles a eritromicina y 3 cepas no sensibles a levofloxacino. CONCLUSIONES: Los resultados de este estudio muestran que los serotipos más frecuentes entre los pacientes con ENI atendidos en nuestro hospital no están cubiertos por las vacunas conjugadas, aunque sí por la VNP23. El serotipo 6C, no cubierto por ninguna vacuna, se situó entre los tres más frecuentemente aislados, causando exitus en un tercio de los pacientes.

Enfermedad neumocócica invasiva en el Hospital Costa del Sol: emergencia de serotipos no vacunables / Invasive neumococcal disease in Costa del Sol Hospital: emergency by non-vaccinable serotypes

Fundamentos: Streptococcus pneumoniae puede causar enfermedades invasivas y no invasivas. Bajo la denominación de enfermedad neumocócica invasiva, se incluyen aquellas infecciones que se localizan en tejidos, órganos y fluidos que normalmente son estériles y que se asocian con procesos clínicos generalmente severos. El objetivo de este estudio fue caracterizar los episodios de ENI (Enfermedad Neumocócica Invasiva) así como describir la sensibilidad antimicrobiana y distribución de los serotipos (vacunales y no vacunales) de cepas de S. pneumoniae aisladas en hemocultivos de pacientes atendidos en el Hospital Costa del Sol entre septiembre de 2012 y enero de 2017. Métodos: Estudio descriptivo a partir de cepas de S. pneumoniae aisladas en hemocultivos. Las variables de estudio fueron: edad, sexo, fallecimiento, tabaquismo, infección por VIH, diagnóstico clínico, serotipo y perfil de sensibilidad antimicrobiana. La fuente de información utilizada fue el programa de gestión clínica "Doctor ". El análisis estadístico se llevó a cabo mediante el software SPSS (SPSS, version 15,0; SPSS, Chicago Illinois, USA). Resultados: Se aislaron un total de 76 cepas de S. pneumoniae. Los serotipos más prevalentes fueron, en orden descendente 8, 3, 9N, 6C, 22F, 11A y 14. El 77,3% de las cepas fueron causantes de episodios de ENI con diagnóstico clínico de neumonía bacteriémica. Según el criterio del CLSI 2016 (Clinical & Laboratory Standards Institute), encontramos 2 cepas no sensibles a penicilina, 23 cepas no sensibles a eritromicina y 3 cepas no sensibles a levofloxacino. Conclusiones: Los resultados de este estudio muestran que los serotipos más frecuentes entre los pacientes con ENI atendidos en nuestro hospital no están cubiertos por las vacunas conjugadas, aunque sí por la VNP23. El serotipo 6C, no cubierto por ninguna vacuna, se situó entre los tres más frecuentemente aislados, causando exitus en un tercio de los pacientes

Background: Streptococcus pneumoniae can cause invasive and noninvasive diseases. Invasive pneumococcal disease causes infections in tissues, organs and fluids that are normally sterile and is associated with severe clinical processes generally. The aim of this study was to characterize ENI episodes as well as to describe the antimicrobial susceptibility and distribution of serotypes (vaccinal and non-vacunal) of S. pneumoniae strains isolated in blood cultures of patients treated at the Hospital Costa del Sol between September 2012 and January 2017. Methods: Descriptive study from S. pneumoniae strains isolated in blood cultures. The variables studied were: age, sex, death, smoking, HIV infection, clinical diagnosis, serotype and antibiotic susceptibility profile. The source of information used was the clinic management program called Doctor. Results: 76 S. pneumoniae strains were isolated. The most prevalent serotypes were 8, 3, 9N, 6C, 22F, 11A and 14. 77.3% of the strains were responsible for IPD (Invasive Pneumococcal Disease) episodes with clinical diagnosis of bacterial pneumonia. According to the CLSI 2016 (Clinical & Laboratory Standards Institute) criteria, 2 strains were non-susceptible to penicillin, 23 strains were non-susceptible to erythromycin and 3 were strains non-susceptible to levofloxacin. Conclusions: The results of this study show that the most frequent serotypes among ENI patients attended in our hospital are not covered by conjugate vaccines, although they do so by VNP23. Serotype 6C, not covered by any vaccine, was among the three most frequently isolated, causing death in one third of patients

Gender and age differences in components of traffic-related pedestrian death rates: exposure, risk of crash and fatality rate.

BACKGROUND: This ecological study aimed i) to quantify the association of age and gender with the three components of pedestrians' death rates after a pedestrian-vehicle crash: exposure, risk of crash and fatality, and ii) to determine the contribution of each component to differences in death rates according to age and gender in Spain. METHODS: We analyzed data for 220 665 pedestrians involved in road crashes recorded in the Spanish registry of road crashes with victims from 1993 to 2011, and a subset of 39 743 pedestrians involved in clean collisions (in which the pedestrian did not commit an infraction). Using decomposition and quasi-induced exposure methods, we obtained the proportion of increase in death rates for each age and gender group associated with exposure, risk of collision and fatality. RESULTS: Death rates increased with age. The main contributor to this increase was fatality, although exposure also increased with age. In contrast, the risk of collision decreased with age. Males had higher death rates than females, especially in the 24-54 year old group. Higher fatality rates in males were the main determinant of this difference, which was also related with a higher risk of collision in males. However, exposure rates were higher in females. CONCLUSIONS: The magnitude and direction of the associations between age and gender and each of the three components of pedestrians' death rates differed depending on the specific component explored. These differences need to be taken into account in order to prioritize preventive strategies intended to decrease mortality among pedestrians.

Erratum to: Gender and age differences in components of traffic-related pedestrian death rates: exposure, risk of crash and fatality rate.

[This corrects the article DOI: 10.1186/s40621-016-0079-2.].

[Contribution of Electronic Health Record in Surveillance of Notifiable Diseases]. / Aportación de la historia clínica digital a la vigilancia de enfermedades de declaración obligatoria.

BACKGROUND: In 2009 a system was introduced for the automatic import (AI) of cases with suspected notifiable diseases (ND) from electronic medical record (EMR) to RedAlerta, an application for surveillance in Andalusia. At present, the contribution of this system to classical active statement has not been determined enough. The main objective of this study is to evaluate the usefulness of IA in the province of Granada, between 2009 and 2014. METHODS: During the study period (2009-2014), an epidemiologist assessed whether AI met declaration criteria or not. We calculate the contribution of AI to RedAlerta and the percentage of validation of AI, estimating 95% CI. RESULTS: The contribution of AI was 17.3% (95% CI 16.1 to 18.5); and type of statement, 5.2% (95% CI 4.1 to 6.5) for urgent and 24.4% (95% CI 22.7 to 26.2) for ordinary. The contribution was higher (more than 45%) in Lyme disease, congenital hypothyroidism, genital herpes, hepatitis C and other viral hepatitis. 30% (95% CI 28.1 to 32) of AI were validated; 39.9% (95% CI 33 to 47.2) urgent and 29.1% (95% CI 27.2 to 31.2%) ordinary. The percentage of validation was higher than 45% (between 47.5 and 100%) in vaccine-preventable diseases, sexually transmitted infections and low incidence. CONCLUSIONS: Although not replace manual reporting and requires verification, the AI system is useful and increases the completeness of the epidemiological surveillance system.

Aportación de la historia clínica digital a la vigilancia de enfermedades de declaración obligatoria / Contribution of electronic health record in surveillance of notifiable diseases

Fundamentos: En 2009 se implantó el sistema para la importación automática (IA) de casos con sospecha de enfermedad de declaración obligatoria (EDO) desde la historia clínica digital (HCD) a la RedAlerta, aplicación informática para la vigilancia epidemiológica en Andalucía. Hasta ahora, la contribución de este sistema a la clásica declaración activa no se ha determinado suficientemente. El principal objetivo de este estudio es evaluar la utilidad de IA en la provincia de Granada, entre 2009 y 2014. Métodos: Durante el periodo de estudio (2009-2014), un epidemiólogo validó si las EDO importadas satisfacían el criterio de declaración o no. Se halló la contribución de la IA a la RedAlerta y el porcentaje de validación de IA, estimando su IC 95%.Resultados: La contribución de la IA fue del 17,3% (IC95%: 16,1-18,5). Por tipo de declaración el 5,2% (IC95%:4,1-6,5) fueron las urgentes y 24,4% (IC95%: 22,7-26,2) fueron ordinarias. La contribución fue superior al 45% en la enfermedad de Lyme, hipotiroidismo congénito, herpes genital, hepatitis C y otras hepatitis víricas. El 30% (IC95%:28,1-32) de las IA fueron validadas de las cuales el 39,9% (IC95%:33–47,2) fueron urgentes y el 29,1% (IC95%:27,2–31,2%) ordinarias. El porcentaje de validación fue superior al 45% (entre el 47,5 y el 100%) en enfermedades vacunables, en las de transmisión sexual y en las de baja incidencia. Conclusiones: Si bien no sustituye la declaración manual y requiere de un proceso de verificación, el sistema de incorporación automática es útil e incrementa la exhaustividad del sistema de vigilancia epidemiológica (AU)

Background: In 2009 a system was introduced for the automatic import (AI) of cases with suspected notifiable diseases (ND) from electronic medical record (EMR) to RedAlerta, an application for surveillance in Andalusia. At present, the contribution of this system to classical active statement has not been determined enough. The main objective of this study is to evaluate the usefulness of IA in the province of Granada, between 2009 and 2014. Methods: During the study period (2009-2014), an epidemiologist assessed whether AI met declaration criteria or not. We calculate the contribution of AI to RedAlerta and the percentage of validation of AI, estimating 95% CI. Results: The contribution of AI was 17.3% (95% CI 16.1 to 18.5); and type of statement, 5.2% (95% CI 4.1 to 6.5) for urgent and 24.4% (95% CI 22.7 to 26.2) for ordinary. The contribution was higher (more than 45%) in Lyme disease, congenital hypothyroidism, genital herpes, hepatitis C and other viral hepatitis. 30% (95% CI 28.1 to 32) of AI were validated; 39.9% (95% CI 33 to 47.2) urgent and 29.1% (95% CI 27.2 to 31.2%) ordinary. The percentage of validation was higher than 45 % (between 47.5 and 100%) in vaccine-preventable diseases, sexually transmitted infections and low incidence. Conclusions: Although not replace manual reporting and requires verification, the AI system is useful and increases the completeness of the epidemiological surveillance system (AU)

Encuesta epidemiológica frente a historia clínica digital en la investigación de un brote por Cryptosporidium en una guardería / Epidemiological survey versus the electronic medical record in the investigation of a Cryptosporidium outbreak in a dayschool

No disponible